Mental Health, Social Influences, and HIV Pre-exposure Prophylaxis (PrEP) Utilization Among Men and Transgender Individuals Screening for HIV Prevention Trials.

Szczegóły
Abstrakt

Tytuł:: Mental Health, Social Influences, and HIV Pre-exposure Prophylaxis (PrEP) Utilization Among Men and Transgender Individuals Screening for HIV Prevention Trials.
Autorzy:: Wood SM; The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA. .; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. .; Roberts Center for Pediatric Research, The Children's Hospital of Philadelphia, 11th Floor, Room 11212, 2716 South St., Philadelphia, PA, 19146, USA. .
Morales KH; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Metzger D; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Davis A; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Fiore D; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Petsis D; The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Barnett K; The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
Koenig HC; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Dowshen N; The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Gross R; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Frank I; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Źródło:: AIDS and behavior [AIDS Behav] 2021 Feb; Vol. 25 (2), pp. 524-531.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: 2005- : New York, NY : Springer Science + Business Media
Original Publication: New York, NY : Plenum Press, 1997-
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/prevention & control
Mental Health*
Pre-Exposure Prophylaxis*
Transgender Persons*
Adult ; Cross-Sectional Studies ; Homosexuality, Male ; Humans ; Male
References:: J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):15-20. (PMID: 27552158)
Lancet. 2014 Feb 1;383(9915):399-400. (PMID: 24494225)
J Adolesc Health. 2017 May;60(5):549-555. (PMID: 28132744)
Ann Epidemiol. 2017 Mar;27(3):176-180. (PMID: 28003117)
PLoS One. 2012;7(3):e33119. (PMID: 22470438)
Am J Public Health. 2012 Sep;102(9):1751-7. (PMID: 22873480)
AIDS Behav. 2009 Aug;13(4):798-810. (PMID: 19462228)
Ann Epidemiol. 2018 Dec;28(12):841-849. (PMID: 29983236)
J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):181-7. (PMID: 21857529)
AIDS Behav. 2018 Apr;22(4):1096-1099. (PMID: 29243109)
Sex Transm Dis. 2016 Nov;43(11):717-723. (PMID: 27893604)
AIDS Behav. 2009 Aug;13(4):811-21. (PMID: 18709453)
AIDS. 2017 Mar 13;31(5):731-734. (PMID: 28060019)
J Acquir Immune Defic Syndr. 2008 May 1;48(1):97-103. (PMID: 18344875)
J Clin Psychol. 1991 Nov;47(6):756-61. (PMID: 1757578)
Clin Infect Dis. 2015 Nov 15;61(10):1590-7. (PMID: 26270691)
Lancet Infect Dis. 2013 Mar;13(3):214-22. (PMID: 23260128)
JMIR Mhealth Uhealth. 2018 Sep 10;6(9):e10456. (PMID: 30201601)
PLoS One. 2015 Jun 03;10(6):e0128971. (PMID: 26039511)
J Homosex. 2006;51(1):111-28. (PMID: 16893828)
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):21-29. (PMID: 27632233)
AIDS Behav. 2017 Jun;21(6):1665-1675. (PMID: 27475943)
Int J STD AIDS. 2020 Apr;31(5):440-446. (PMID: 32208815)
J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):285-292. (PMID: 28187084)
AIDS Behav. 2008 Jan;12(1):1-17. (PMID: 17694429)
AIDS Behav. 2016 Jul;20(7):1470-7. (PMID: 26336946)
AIDS Behav. 2016 Jul;20(7):1478-88. (PMID: 26078115)
AIDS Behav. 2013 Jul;17(6):2180-4. (PMID: 23479003)
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):384-90. (PMID: 18091609)
AIDS Behav. 2013 Jun;17(5):1764-9. (PMID: 23605154)
AIDS Care. 2017 Sep;29(9):1153-1161. (PMID: 28488886)
J Affect Disord. 2009 Apr;114(1-3):163-73. (PMID: 18752852)
AIDS Behav. 2016 Jul;20(7):1527-34. (PMID: 27125241)
J Pers Assess. 1990 Winter;55(3-4):610-7. (PMID: 2280326)
AIDS Behav. 2018 Nov;22(11):3673-3680. (PMID: 29754268)
J Gen Intern Med. 2001 Sep;16(9):606-13. (PMID: 11556941)
AIDS. 2015 Jul 17;29(11):1277-85. (PMID: 26103095)
Grant Information:: P30 MH 097488 Penn Mental Health AIDS Research Center; Pilot Grant CHOP Research Institute; UM1 AI069534 United States AI NIAID NIH HHS; P30 AI 045008 Center for AIDS Research, University of Pennsylvania; P30 AI045008 United States AI NIAID NIH HHS; K23MH102128 United States MH NIMH NIH HHS; P30 MH097488 United States MH NIMH NIH HHS; K23MH119976 United States MH NIMH NIH HHS; F32 MH111341 United States MH NIMH NIH HHS; K23 MH102128 United States MH NIMH NIH HHS; K23 MH119976 United States MH NIMH NIH HHS
Contributed Indexing:: Keywords: Depression; HIV; Pre-exposure prophylaxis; Social networks
Substance Nomenclature:: 0 (Anti-HIV Agents)
Entry Date(s):: Date Created: 20200830 Date Completed: 20210212 Latest Revision: 20231108
Update Code:: 20240105
PubMed Central ID:: PMC8546869
DOI:: 10.1007/s10461-020-03004-y
PMID:: 32860114
: Czasopismo naukowe

Full Text Finder

The effects of mental health comorbidities and social support on the HIV pre-exposure prophylaxis (PrEP) care continuum are unknown. We conducted a cross-sectional study of men and transgender individuals, ≥ 18 years-old, with ≥ 2 male or transgender partners, or recent condomless anal intercourse. Surveys assessed demographics, mental health treatment, depressive symptomatology, social support, and PrEP-related social contacts. Logistic regression assessed associations between these factors and PrEP uptake and persistence. Participants (n = 247) were 89% cis-male and 46% African-American. Median age was 27 (IQR:23-33). Thirty-seven percent had ever used PrEP, of whom 18% discontinued use. High depressive symptomology was identified in 11% and 9% were receiving mental health treatment. There were no significant associations between depressive symptoms or mental health treatment on the odds of PrEP uptake or discontinuation. Each additional PrEP contact conferred a greater odds of uptake (aOR:1.24, 95% CI: 1.09-1.42). Network-level targets may produce fruitful interventions to increase PrEP uptake.

Informacja